Published by Chemical Research Insight, April 2026 A 2026 industry special report covering global vaccine glass packaging manufacturers records rapid breakthroughs in China’s neutral borosilicate pharmaceutical glass sector. Driven by domestic injection consistency evaluation policies, the self-sufficiency rate of domestic Type I borosilicate glass tubing rose to 58.4% by the end of 2025, breaking long-term monopoly by SCHOTT and Corning. Domestic leading glass enterprises including Shandong Pharmaceutical Glass, Linuo and Four Stars Glass expanded kiln and cleanroom capacity massively, supporting matched mass production of supporting halobutyl stoppers and 20mm aluminum plastic flip caps. Complete integrated packaging kits (vial + rubber stopper + aluminum cap) produced by Chinese manufacturers have become mainstream imported solutions for pharmaceutical factories across Indonesia, Vietnam and Thailand in late 2025 and early 2026. Local Southeast Asian pharmaceutical companies rely heavily on imported high-standard injectable packaging, and Chinese products stand out for balanced certification qualifications, competitive pricing and flexible small-batch customized services. Most Chinese suppliers can provide full GMP, ISO15378 and pharmacopoeia compliance documents, and many factories have completed local country registration in Indonesia and Malaysia to clear customs faster. Cross-border B2B platforms like Made-in-China evolve into core sales channels for small and medium-sized Nanjing, Jiangsu-based pharmaceutical packaging foreign trade companies, helping them connect hundreds of regional pharmaceutical purchasers without expensive overseas exhibition costs. Industry insiders forecast that Southeast Asia will maintain double-digit annual order growth for Chinese pharmaceutical packaging throughout 2027, with lyophilization vial sets and vaccine sealing components as top demand categories.
18014828823
Message